Recent developments in HIV prevention — including the FDA approval of a 6‑month injectable option and updated clinical guidance — are changing the landscape of Pre-Exposure Prophylaxis (PrEP) therapy. This course reviews the latest developments, compares prevention strategies, and examines how these changes affect PrEP delivery, counseling, and monitoring. You will gain timely insights to better counsel patients, support adherence, and contribute to prevention strategies in your practice.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls
GUEST
David Hachey, PharmD, AAHIVP
Professor
Idaho State University
Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe key new HIV PrEP therapy options recently approved or recommended, including their dosing schedules and clinical indications.
2. Identify pharmacist responsibilities when counseling patients about PrEP, including initiation, adherence, monitoring, and risk-benefit discussions.
Rachel Maynard and David Hachey have no relevant financial relationships to disclose.
0.05 CEU/0.5 Hr
UAN: 0107-0000-26-049-H01-P
Initial release date: 2/9/2026
Expiration date: 2/9/2027
Additional CPE details can be found here.
